NHS England’s controversial £330m data deal with Palantir draws mixed reactions
NHS England’s recent decision to award the £330 million Federated Data Platform (FDP) contract to US data analytics firm Palantir, in collaboration with Accenture, PwC, NECS, and Carnall Farrar, has elicited a spectrum of reactions. This announcement marks a significant step in NHS’s digital transformation efforts, with the FDP designed to connect and streamline access to...Read Moreby Nicholas FeenieDecember 11, 2023 Asia, Obesity and Population Health, Obesity and the Economy, Obesogenic Environment0 comments
UK’s obesity challenge: Learning from Japan’s effective approach
In Japan, a unique festive tradition involving Colonel Sanders statues dressed as Santa Claus outside KFC branches marks the start of the Christmas season. This tradition, a result of a marketing strategy from the 1970s, has become a cultural phenomenon, with millions participating in the “KFC Special Christmas Dinner”. This period is significant for KFC Japan, contributing to a...Read MoreSingapore forges ahead with digital health initiatives to address healthcare workforce shortages
In Singapore, healthcare leaders and young professionals are uniting under a common goal: to create a more integrated and sustainable healthcare system, leveraging digital technologies. This ambition aligns with findings from the Future Health Index 2023 report by Royal Philips, highlighting Singapore’s dedicated efforts in digital health transformation. These findings reflect broader...Read MoreOxford study shows doctors’ communication style crucial for patient weight loss success
A groundbreaking study from the University of Oxford, recently published in the Annals of Internal Medicine, has revealed that the manner in which doctors communicate with patients about obesity plays a pivotal role in their weight loss success. This innovative research delves into the nuances of communication, showing that not only do the words doctors use matter, but also their tone and...Read MoreSwiss pharmaceutical giant Roche enters obesity drug race with $2.7 billion Carmot deal
Swiss pharmaceutical giant, Roche, has announced a significant strategic move in the obesity treatment market with its $2.7 billion acquisition of Carmot Therapeutics, a U.S.-based obesity drug developer. This places Roche among leading contenders like Novo Nordisk and Eli Lilly in the weight-loss drug sector. Carmot’s flagship product, CT-388, a once-a-week dual GLP-1/GIP receptor...Read Moreby Nicholas FeenieDecember 5, 2023 Obesity and the Economy, Obesity in the UK, Obesity Policy, Obesogenic Environment1 comment